Key facts
- It has raised $43.1M across 1 recorded rounds; the latest was Early Stage VC ($34.3M) in Aug 2024.
- Notable investors include University of Toronto, BDC Capital, University of Toronto Entrepreneurship, Alexandria Venture Investments, Gates Foundation — 10 tracked in total.
- Radiant Biotherapeutics has filed 1 Form D with the SEC, most recently Oct 2024 ($34.3M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Radiant Biotherapeutics
Funding rounds
1 roundsAbout Radiant Biotherapeutics
Developer of a modular multi-valent and multi-specific platform intended to create antibodies for the treatment of cancer, inflammation, and infections. The company's platform offers multi-functional biologics to tackle difficult-to-treat diseases such as cancer, auto-immune and infectious diseases, enabling healthcare professionals to exploit avidity, binding power coupled with multi-specificity to deliver potent multi-functional biologics with the potential to unlock cures for patients.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2020
- Employees
- 14
- Website
- radiantbio.com/
- Ownership
- Privately Held (backing)
Radiant Biotherapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Radiant Biotherapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Radiant Biotherapeutics in its N-PORT filings yet. We sweep new filings monthly.